Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 578-580

  Markman, Maurie ^a,b   Kulp, Barbara ^b   Peterson, Gertrude ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Liposomal doxorubicin; Ovarian cancer; Sunburn

Indexed keywords

DOXORUBICIN; LIPOSOME; PLATINUM; PYRIDOXINE; STEROID;

ADULT; ANAMNESIS; ARTICLE; BLISTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CLINICAL FEATURE; CONVALESCENCE; CREAM; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; FOOT DISEASE; HAND FOOT SYNDROME; HUMAN; OVARY CARCINOMA; PAIN; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN DISEASE; SKIN TOXICITY; SKIN ULCER; SUNBURN;

DOXORUBICIN; DRUG ERUPTIONS; ERYTHEMA; FEMALE; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; SUNBURN;

EID: 3543065192     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.002     Document Type: Article

References (22)

1. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase: III. Study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19:2001;3312-3322
2. Israel V.P., Garcia A.A., Roman L., Muderspach L., Burnett A., Jeffers S., et al. Phase: II. Study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol. Oncol. 78:2000;143-147
3. Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., et al. Phase: II. Study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15:1997;987-993
4. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., Belinson J. Phase: 2. Trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel- refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol. 78:2000;369-372
5. Campos S.M., Penson R.T., Mays A.R., Berkowitz R.S., Fuller A.F., Goodman A., et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol. Oncol. 81:2001;206-212
6. Rose P.G., Hawthorne Maxson J., Fusco N., Mossbruger K., Rodriguez M. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol. Oncol. 82:2001;323-328
7. Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase: I. Studies. J. Clin. Oncol. 13:1995;1777-1785
8. Ranson M.R., Carmichael J., O'Byrne K., Stewart S., Smith D., Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase: II. Trial. J. Clin. Oncol. 15:1997;3185-3191
9. Caponigro F., Comella P., Budillon A., Bryce J., Avallone A., DeRosa V., et al. Phase: I. Study of calyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann. Oncol. 11:2000;339-342
10. Lyass O., Uziely B., Ben-Yosef R., Tzemach D., Heshing N.I., Lotem M., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer. 89:2000;1037-1047
11. Coukell A.J., Spencer C.M. Polyethylene glycol-liposomal doxorubicin. Drugs. 53:1997;520-538
12. Lokich J.J., Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann. Intern. Med. 101:1984;798-800
13. Nagore E., Insa A., Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am. J. Clin. Dermatol. 1:2000;225-234
14. Vail D.M., Kravis L.D., Cooley A.J., Chun R., MacEwen E.G. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother. Pharmacol. 39:1997;410-416
15. Vail D.M., Chun R., Thamm D.H., Garrett L.D., Cooley A.J., Obradovich J.E. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin. Cancer Res. 4:1998;1567-1571
16. Vukelja S.J., Baker W.J. III, Burris H.A., Keeling J.H., Von Hoff D. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J. Natl. Cancer Inst. 85:1993;1432
17. Fabian C.J., Molina R., Slavik M., Dahlberg S., Giri S., Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest. New Drugs. 8:1990;57-63
18. Escobar P., Markman M., Zanotti K., Webster K., Belinson J. Phase: 2. Trial of liposomal doxorubicin in advanced endometrial cancer. J. Cancer Res. Clin. Oncol. 129:2003;651-654
19. Cassady J.R., Richter M.P., Piro A.J., Jaffe N. Radiation-adriamycin interactions: preliminary clinical observations. Cancer. 36:1975;946-949
20. Fontana J.A. Radiation recall associated with VP-16-213 therapy. Cancer Treat. Rep. 63:1979;224-225
21. Stelzer K.J., Griffin T.W., Koh W.J. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer. 71:1993;1322-1325
22. Hui Fung Y., Giles F.J., Cortes J.E. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome - Recall following different chemotherapy agents. Invest. New Drugs. 20:2002;49-53